XTL Biopharmaceuticals
XTLB
3 hedge funds and large institutions have $463K invested in XTL Biopharmaceuticals in 2024 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.07% less ownership
Funds ownership: 4.26% → 4.19% (-0.07%)
17% less capital invested
Capital invested by funds: $556K → $463K (-$93.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$8.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$15.4K |
XTLB Hedge Fund Activity: Q4 2024 in Review
3 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2024, worth a combined $463K — down 17% from $556K a quarter earlier.
Fund positioning in XTLB was balanced in Q4 2024: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was RhumbLine Advisers, adding an estimated $8.43K. The largest seller was Morgan Stanley, cutting an estimated $15.4K.
- 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $463K of XTL Biopharmaceuticals stock for Q4 2024, down 17% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q4 2024 and 0 closed out.
- The largest XTL Biopharmaceuticals buyer in Q4 2024 was RhumbLine Advisers, an estimated $8.43K added.
- The largest XTL Biopharmaceuticals seller in Q4 2024 was Morgan Stanley, an estimated $15.4K sold.
Based on aggregated 13F filings for Q4 2024.